0800 Immune

0800 466 863

Vaccine safety

Pertussis and influenza immunisation coverage of pregnant women in New Zealand

Background: Immunisation is an important public health policy and measuring coverage is imperative to
identify gaps and monitor trends. New Zealand (NZ), like many countries, does not routinely publish coverage
of immunisations given during pregnancy. Therefore, this study examined pregnancy immunisation
coverage of all pregnant NZ women between 2013 and 2018, and what factors affected uptake.
Methods: A retrospective cohort study of pregnant women who delivered between 2013 and 2018 was

A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero

We aimed to evaluate the safety of maternal Tdap; thus, we assessed health events by examining the difference in birth and hospital-related outcomes of infants with and without fetal exposure to Tdap. This was a retrospective cohort study using linked administrative datasets. The study population were all live-born infants in New Zealand (NZ) weighing at least 400 g at delivery and born to women who were eligible for the government funded, national-level vaccination program in 2013. Infants were followed from birth up to one year of age.

Safety monitoring

Throughout the development of a new vaccine, from discovery to marketing and beyond, the safety of each candidate vaccine is carefully assessed. At any stage, development is discontinued if the safety risk outweighs the benefit.

Adverse events following immunisation

Any medical event occurring after immunisation can be classified as an adverse event following immunisation (AEFI) whether the event has any causal relationship to getting the immunisation or not. 

Adverse events/responses following immunisation can range from mild to severe and from common to very rare. They may occur as a result of the immunisation, a causal relationship between the event and immunisation, or occur after the immunisation by chance, a coincidental relationship between the event and immunisation.

Adverse events following immunisation can be classified as: